A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
2021 · BMC Gastroenterology · 68 citations
https://doi.org/10.1186/s12876-021-01660-5
M
Michael H. Cummings
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
65
Papers
1.2K
Citations
20
h-index
26
i10-index
Michael H. Cummings is an academic researcher from Portsmouth Hospitals NHS Trust. The author has contributed to research in topics: Diabetes Treatment and Management & Diabetes Management and Research & Sexual function and dysfunction studies. The author has an h-index of 20, co-authored 56 publications.
Papers by this author
worksLong-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
2020 · Diabetes Therapy · 24 citations
https://doi.org/10.1007/s13300-020-00883-1
Additional file of A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14431721
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat